Latest Biolinerx Ltd (BLRX) Headlines Pipeline
Post# of 82
Posted On: 03/13/2014 6:04:11 AM
Latest Biolinerx Ltd (BLRX) Headlines
Pipeline Update at BioLineRx - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 4:50PM CDT
BioLineRx announced the successful completion of the single administration, dose-escalation stage of the ongoing phase I/II study on BL-7010
IntelliPharmaCeutics (IPCI) Jumps: Stock Up 8.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 7:51AM CDT
IntelliPharmaCeutics International Inc. was a big mover last session, as its shares rose nearly 9% on the day.
BioLineRx to Report Fourth Quarter and Year End 2013 Results on March 17, 2014
Business Wire - Tue Mar 11, 6:01AM CDT
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it will release its financial results for the quarter and year ended December 31, 2013 on Monday, March 17, 2014, before the U.S. markets open.
BioLineRx Completes Dose Escalation Stage of Phase 1/2 Study for Novel Celiac Treatment
Business Wire - Mon Mar 10, 6:00AM CDT
--BL-7010 now advancing to repeated administration part of study; results expected mid 2014
BioLineRx Closes $24.1 Million Underwritten Public Offering of its American Depositary Shares
Business Wire - Fri Mar 07, 11:00AM CST
BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today announced that it has closed its previously announced underwritten public offering of 9,660,000 American Depositary Shares ("ADSs"), each representing ten (10) of its Ordinary Shares, at a public offering price of $2.50 per ADS, for gross proceeds of approximately $24.1 million. All of the ADSs in the offering were sold by BioLineRx. The amount of ADSs sold includes an additional 1,260,000 ADSs purchased by the underwriters pursuant to the over-allotment option granted to them by BioLineRx.
OncoGenex Pharmaceuticals (OGXI) Soars: Stock Up 6.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 7:51AM CST
OncoGenex Pharmaceuticals, Inc. was a big mover last session, as its shares rose nearly 7% on the day.
Portola Pharmaceuticals (PTLA) Jumps: Stock Up 8.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 7:51AM CST
Portola Pharmaceuticals, Inc. was a big mover last session, as its shares rose over 8% on the day.
BioLineRx to Present at the Annual ROTH Growth Stock Conference in California
Business Wire - Wed Mar 05, 6:03AM CST
BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky, Ph.D., and its Chief Financial and Operating Officer, Philip Serlin, will be presenting at the 26th Annual ROTH Growth Stock Conference being held at the Ritz Carlton in Dana Point, CA.
Nektar Therapeutics (NKTR) Jumps: Stock Up 10.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 8:39AM CST
Nektar Therapeutics was a big mover last session, as its shares rose nearly 11% on the day.
BioLineRx Prices $21.0 Million Underwritten Public Offering of its American Depositary Shares
Business Wire - Tue Mar 04, 8:07AM CST
BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today announced that it has priced an underwritten public offering of 8,400,000 American Depositary Shares ("ADSs"), each representing ten (10) of its Ordinary Shares, at a public offering price of $2.50 per ADS for gross proceeds of $21.0 million. All of the ADSs in the offering are to be sold by BioLineRx. Delivery of the ADSs is expected to occur on March 7, 2014. BioLineRx has granted the underwriters a 30-day option to purchase up to an additional 1,260,000 ADSs to cover over-allotments, if any.
Can Auxilium Pharma (AUXL) Continue to Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 7:30AM CST
Auxilium Pharma has seen its Zacks Rank surge over the past four weeks, moving from Hold territory to its current position as a Strong Buy.
BioLineRx Announces Underwritten Public Offering of its American Depositary Shares
PR Newswire - Mon Mar 03, 3:35PM CST
BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today announced that it has commenced an underwritten public offering of its American Depositary Shares ("ADSs"), each representing ten (10) of its Ordinary Shares. All of the ADSs in the offering are to be sold by BioLineRx.
BioLineRx appoints Dr Sandra Panem to board
M2 - Tue Feb 25, 5:59AM CST
Biopharmaceutical company BioLineRx (NASDAQ:BLRX)(TASE:BLRX), headquartered in Israel, revealed on Monday the addition of Dr Sandra Panem PhD to its board of directors.
BioLineRx Appoints Dr. Sandra Panem to Board of Directors
PR Newswire - Mon Feb 24, 6:00AM CST
BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today the appointment of Sandra Panem, Ph.D., to its Board of Directors.
Data on BioLineRx's BL-8040 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 13, 5:30PM CST
BioLineRx recently announced positive preclinical results on candidate BL-8040 for the indication of chronic myeloid leukemia (CML).
BioLineRx Announces Positive Preclinical Results for Novel Treatment for Chronic Myeloid Leukemia
PR Newswire - Wed Feb 12, 6:00AM CST
BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today positive pre-clinical results for BL-8040 in a third indication - as a treatment for chronic myeloid leukemia. Results of the study were recently published in Molecular Cancer Therapeutics.
BioLineRx to Present at the 2014 BIO CEO & Investor Conference in New York on February 10
PR Newswire - Mon Feb 03, 6:00AM CST
BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky, Ph.D., and its Chief Financial and Operating Officer, Philip Serlin, will present a company update at the BIO CEO & Investor Conference on Monday, February 10, 2014 at 2:30 p.m. EST. The conference will be held at the Waldorf Astoria in New York.
Update on BioLineRx' BL-8040 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 27, 4:10PM CST
The FDA granted an orphan drug designation to BioLineRx' BL-8040 for the treatment of stem cell mobilization.
BioLineRx Receives Orphan Drug Designation for Novel Stem Cell Mobilization Treatment
PR Newswire - Thu Jan 23, 6:00AM CST
BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has received notice from the U.S. Food & Drug Administration (FDA) confirming an Orphan Drug Designation of BL-8040 as a treatment for stem cell mobilization, in addition to the Orphan Drug Designation previously granted to BL-8040 as a treatment for Acute Myeloid Leukemia (AML).
Update on BioLineRx's BL-5010 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 22, 5:00PM CST
BioLineRx gained approval to start a pivotal, CE Mark registration trial for BL-5010P for novel skin lesion treatment
Pipeline Update at BioLineRx - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 4:50PM CDT
BioLineRx announced the successful completion of the single administration, dose-escalation stage of the ongoing phase I/II study on BL-7010
IntelliPharmaCeutics (IPCI) Jumps: Stock Up 8.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 7:51AM CDT
IntelliPharmaCeutics International Inc. was a big mover last session, as its shares rose nearly 9% on the day.
BioLineRx to Report Fourth Quarter and Year End 2013 Results on March 17, 2014
Business Wire - Tue Mar 11, 6:01AM CDT
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it will release its financial results for the quarter and year ended December 31, 2013 on Monday, March 17, 2014, before the U.S. markets open.
BioLineRx Completes Dose Escalation Stage of Phase 1/2 Study for Novel Celiac Treatment
Business Wire - Mon Mar 10, 6:00AM CDT
--BL-7010 now advancing to repeated administration part of study; results expected mid 2014
BioLineRx Closes $24.1 Million Underwritten Public Offering of its American Depositary Shares
Business Wire - Fri Mar 07, 11:00AM CST
BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today announced that it has closed its previously announced underwritten public offering of 9,660,000 American Depositary Shares ("ADSs"), each representing ten (10) of its Ordinary Shares, at a public offering price of $2.50 per ADS, for gross proceeds of approximately $24.1 million. All of the ADSs in the offering were sold by BioLineRx. The amount of ADSs sold includes an additional 1,260,000 ADSs purchased by the underwriters pursuant to the over-allotment option granted to them by BioLineRx.
OncoGenex Pharmaceuticals (OGXI) Soars: Stock Up 6.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 7:51AM CST
OncoGenex Pharmaceuticals, Inc. was a big mover last session, as its shares rose nearly 7% on the day.
Portola Pharmaceuticals (PTLA) Jumps: Stock Up 8.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 7:51AM CST
Portola Pharmaceuticals, Inc. was a big mover last session, as its shares rose over 8% on the day.
BioLineRx to Present at the Annual ROTH Growth Stock Conference in California
Business Wire - Wed Mar 05, 6:03AM CST
BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky, Ph.D., and its Chief Financial and Operating Officer, Philip Serlin, will be presenting at the 26th Annual ROTH Growth Stock Conference being held at the Ritz Carlton in Dana Point, CA.
Nektar Therapeutics (NKTR) Jumps: Stock Up 10.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 8:39AM CST
Nektar Therapeutics was a big mover last session, as its shares rose nearly 11% on the day.
BioLineRx Prices $21.0 Million Underwritten Public Offering of its American Depositary Shares
Business Wire - Tue Mar 04, 8:07AM CST
BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today announced that it has priced an underwritten public offering of 8,400,000 American Depositary Shares ("ADSs"), each representing ten (10) of its Ordinary Shares, at a public offering price of $2.50 per ADS for gross proceeds of $21.0 million. All of the ADSs in the offering are to be sold by BioLineRx. Delivery of the ADSs is expected to occur on March 7, 2014. BioLineRx has granted the underwriters a 30-day option to purchase up to an additional 1,260,000 ADSs to cover over-allotments, if any.
Can Auxilium Pharma (AUXL) Continue to Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 7:30AM CST
Auxilium Pharma has seen its Zacks Rank surge over the past four weeks, moving from Hold territory to its current position as a Strong Buy.
BioLineRx Announces Underwritten Public Offering of its American Depositary Shares
PR Newswire - Mon Mar 03, 3:35PM CST
BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today announced that it has commenced an underwritten public offering of its American Depositary Shares ("ADSs"), each representing ten (10) of its Ordinary Shares. All of the ADSs in the offering are to be sold by BioLineRx.
BioLineRx appoints Dr Sandra Panem to board
M2 - Tue Feb 25, 5:59AM CST
Biopharmaceutical company BioLineRx (NASDAQ:BLRX)(TASE:BLRX), headquartered in Israel, revealed on Monday the addition of Dr Sandra Panem PhD to its board of directors.
BioLineRx Appoints Dr. Sandra Panem to Board of Directors
PR Newswire - Mon Feb 24, 6:00AM CST
BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today the appointment of Sandra Panem, Ph.D., to its Board of Directors.
Data on BioLineRx's BL-8040 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 13, 5:30PM CST
BioLineRx recently announced positive preclinical results on candidate BL-8040 for the indication of chronic myeloid leukemia (CML).
BioLineRx Announces Positive Preclinical Results for Novel Treatment for Chronic Myeloid Leukemia
PR Newswire - Wed Feb 12, 6:00AM CST
BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today positive pre-clinical results for BL-8040 in a third indication - as a treatment for chronic myeloid leukemia. Results of the study were recently published in Molecular Cancer Therapeutics.
BioLineRx to Present at the 2014 BIO CEO & Investor Conference in New York on February 10
PR Newswire - Mon Feb 03, 6:00AM CST
BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky, Ph.D., and its Chief Financial and Operating Officer, Philip Serlin, will present a company update at the BIO CEO & Investor Conference on Monday, February 10, 2014 at 2:30 p.m. EST. The conference will be held at the Waldorf Astoria in New York.
Update on BioLineRx' BL-8040 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 27, 4:10PM CST
The FDA granted an orphan drug designation to BioLineRx' BL-8040 for the treatment of stem cell mobilization.
BioLineRx Receives Orphan Drug Designation for Novel Stem Cell Mobilization Treatment
PR Newswire - Thu Jan 23, 6:00AM CST
BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has received notice from the U.S. Food & Drug Administration (FDA) confirming an Orphan Drug Designation of BL-8040 as a treatment for stem cell mobilization, in addition to the Orphan Drug Designation previously granted to BL-8040 as a treatment for Acute Myeloid Leukemia (AML).
Update on BioLineRx's BL-5010 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 22, 5:00PM CST
BioLineRx gained approval to start a pivotal, CE Mark registration trial for BL-5010P for novel skin lesion treatment
(0)
(0)Biolinerx Ltd. (BLRX) Stock Research Links
Scroll down for more posts ▼